A nanotherapeutic strategy to target drug-tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer

Cancer Commun (Lond). 2023 Apr;43(4):503-507. doi: 10.1002/cac2.12401. Epub 2023 Jan 24.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • ErbB Receptors
  • Humans
  • Lung Neoplasms* / drug therapy
  • Tyrosine Kinase Inhibitors

Substances

  • Tyrosine Kinase Inhibitors
  • ErbB Receptors
  • EGFR protein, human